Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma
- PMID: 36651471
- DOI: 10.2217/fon-2022-0774
Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma
Abstract
Lisocabtagene maraleucel (liso-cel) is one of the three US FDA-approved chimeric antigen receptor T-cell therapies for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). TRANSCEND is the landmark trial that led to the approval of liso-cel in the third-line setting for R/R diffuse LBCL, primary mediastinal B-cell lymphoma, follicular lymphoma grade 3B and transformed lymphoma. The TRANSFORM and PILOT studies evaluated the use of liso-cel in the second-line treatment of R/R LBCL. This review details the structure and manufacturing process of liso-cel that make it distinct from other approved chimeric antigen receptor constructs, outlines results from landmark trials of liso-cel in LBCL and discusses liso-cel toxicity.
Keywords: CAR T-cell therapy; large B-cell lymphoma; lisocabtagene maraleucel.
Plain language summary
Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment for large B-cell lymphoma (LBCL). CAR T involves modifying a patient's immune cells (T cells, specifically), so that they can attack cancer cells and destroy them. Lisocabtagene maraleucel (liso-cel) is a type of CAR T-cell therapy that has been approved to treat patients with LBCL who have already received at least one line of treatment for their lymphoma. This article outlines the structure and manufacturing process of liso-cel and discusses how it differs from other approved CAR T-cell therapies. It also summarizes the clinical data for liso-cel in the treatment of LBCL, as well as its safety and expected side effects.
Similar articles
-
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1. Lancet. 2020. PMID: 32888407 Clinical Trial.
-
Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.Cancer Med. 2022 Dec;11(24):4889-4899. doi: 10.1002/cam4.4820. Epub 2022 May 26. Cancer Med. 2022. PMID: 35619325 Free PMC article. Clinical Trial.
-
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.Lancet. 2022 Jun 18;399(10343):2294-2308. doi: 10.1016/S0140-6736(22)00662-6. Lancet. 2022. PMID: 35717989 Clinical Trial.
-
Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.Expert Rev Anticancer Ther. 2024 Jun;24(6):457-465. doi: 10.1080/14737140.2024.2343801. Epub 2024 Apr 24. Expert Rev Anticancer Ther. 2024. PMID: 38646700
-
Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?Hematol Oncol Stem Cell Ther. 2022 Dec 23;15(4):168-175. doi: 10.1016/j.hemonc.2021.09.004. Hematol Oncol Stem Cell Ther. 2022. PMID: 34699774 Review.
Cited by
-
Recent advances in treatment of nodal and gastrointestinal follicular lymphoma.World J Gastroenterol. 2023 Jun 21;29(23):3574-3594. doi: 10.3748/wjg.v29.i23.3574. World J Gastroenterol. 2023. PMID: 37398889 Free PMC article.
-
Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015-2024).Discov Oncol. 2025 Aug 3;16(1):1461. doi: 10.1007/s12672-025-03360-y. Discov Oncol. 2025. PMID: 40754556 Free PMC article.
-
Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures.Cancers (Basel). 2023 Dec 20;16(1):39. doi: 10.3390/cancers16010039. Cancers (Basel). 2023. PMID: 38201467 Free PMC article. Review.
-
Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas.World J Gastroenterol. 2023 Dec 28;29(48):6179-6197. doi: 10.3748/wjg.v29.i48.6179. World J Gastroenterol. 2023. PMID: 38186866 Free PMC article. Review.
-
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.Int J Mol Sci. 2024 Oct 23;25(21):11384. doi: 10.3390/ijms252111384. Int J Mol Sci. 2024. PMID: 39518937 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
